What can I claim secondary to sarcoidosis?
16 conditions in the Repatriation Medical Authority's Statements of Principles list sarcoidosis as a factor. If DVA has accepted your sarcoidosis, each of these has a documented pathway to a further claim.
At a glance
- Accepted conditionSarcoidosis
- Conditions it may open16
- SourceRMA SoPs
- Chart Review$600 + GST
How a secondary claim works
Some Statement of Principles factors are not about service at all — they name another condition. Where DVA has already accepted your sarcoidosis, and another condition's SoP lists sarcoidosis as a factor, that part of the next claim is already established on your file. How a secondary claim works, in full →
Conditions that list sarcoidosis as a factor
Quoted from the instrument. A pathway existing is not the same as a claim succeeding — each factor carries thresholds your record has to satisfy.
Acute myeloid leukaemia
RH No. 21 of 2024 · BoP No. 22 of 2024
Reasonable Hypothesis — factor (14): “having one of the following autoimmune diseases before clinical onset: (a) autoimmune haemolytic anaemia; (b) giant cell arteritis; (c) pernicious anaemia; (d) polymyalgia rheumatica; (e) rheumatoid arthritis; (f) sarcoidosis; (g) systemic lupus erythematosus; (h) systemic vasculitis; or (i) ulcerative colitis” [clinical onset]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Anosmia
RH No. 19 of 2021 · BoP No. 20 of 2021
Reasonable Hypothesis — factor (4): “having sarcoidosis at the time of the clinical onset of anosmia” [clinical onset]
Balance of Probabilities — factor (4): “having sarcoidosis at the time of the clinical onset of anosmia” [clinical onset]
Atrial fibrillation and atrial flutter
RH No. 1 of 2023 · BoP No. 2 of 2023
Reasonable Hypothesis — factor (30): “having infiltration of the myocardium due to: (a) amyloidosis; (b) haemochromatosis; or (c) sarcoidosis; at the time of the clinical onset of atrial fibrillation or atrial flutter” [clinical onset] — factor (74): “having infiltration of the myocardium due to: (a) amyloidosis; (b) haemochromatosis; or (c) sarcoidosis; at the time of the clinical worsening of atrial fibrillation or atrial flutter” [worsening]
Balance of Probabilities — factor (29): “having infiltration of the myocardium due to amyloidosis or sarcoidosis at the time of the clinical onset of atrial fibrillation or atrial flutter” [clinical onset] — factor (66): “having infiltration of the myocardium due to amyloidosis or sarcoidosis at the time of the clinical worsening of atrial fibrillation or atrial flutter” [worsening]
Bronchiectasis
RH No. 30 of 2017 · BoP No. 31 of 2017
Reasonable Hypothesis — factor (4): “having sarcoidosis of the lung before the clinical onset of bronchiectasis” [clinical onset] — factor (26): “having sarcoidosis of the lung before the clinical worsening of bronchiectasis” [worsening]
Balance of Probabilities — factor (4): “having sarcoidosis of the lung before the clinical onset of bronchiectasis” [clinical onset] — factor (18): “having sarcoidosis of the lung before the clinical worsening of bronchiectasis” [worsening]
Cardiomyopathy
RH No. 57 of 2024 · BoP No. 58 of 2024
Reasonable Hypothesis — factor (6): “having infiltration of the myocardium due to: (a) amyloidosis; (b) iron overload (haemosiderosis); or (c) sarcoidosis; at the time of the clinical onset or clinical worsening” [onset and worsening]
Balance of Probabilities — factor (6): “having infiltration of the myocardium due to: (a) amyloidosis; (b) iron overload (haemosiderosis); or (c) sarcoidosis; at the time of clinical onset or clinical worsening” [onset and worsening]
Note: iron overload is defined in the Schedule 1 - Dictionary.
Duodenal ulcer and duodenal erosion
RH No. 49 of 2024 · BoP No. 50 of 2024
Reasonable Hypothesis — factor (25): “having one of the following medical conditions at the time of clinical onset or clinical worsening; (a) amyloidosis; (b) eosinophilic gastroenteritis; (c) sarcoidosis; (d) systemic mastocytosis; or (e) uraemic gastritis” [onset and worsening]
Balance of Probabilities — factor (19): “having one of the following medical conditions at the time of clinical onset or clinical worsening; (a) amyloidosis; (b) eosinophilic gastroenteritis; (c) sarcoidosis; (d) systemic mastocytosis” [onset and worsening]
Note: systemic mastocytosis is defined in the Schedule 1 - Dictionary.
Gastric ulcer and gastric erosion
RH No. 51 of 2024 · BoP No. 52 of 2024
Reasonable Hypothesis — factor (27): “having one of the following medical conditions at the time of clinical onset or clinical worsening; (a) amyloidosis; (b) eosinophilic gastroenteritis; (c) sarcoidosis; (d) systemic mastocytosis; or (e) uraemic gastritis” [onset and worsening]
Balance of Probabilities — factor (21): “having one of the following medical conditions at the time of clinical onset or clinical worsening; (a) amyloidosis; (b) eosinophilic gastroenteritis; (c) sarcoidosis; (d) systemic mastocytosis” [onset and worsening]
Note: systemic mastocytosis is defined in the Schedule 1 - Dictionary.
Heart block
RH No. 23 of 2022 · BoP No. 24 of 2022
Balance of Probabilities — factor (3): “having infiltration of the myocardium due to amyloidosis or sarcoidosis at the time of the clinical onset of heart block” [clinical onset] — factor (30): “having infiltration of the myocardium due to amyloidosis or sarcoidosis at the time of the clinical worsening of heart block” [worsening]
This condition has a Balance of Probabilities instrument only, so the same test applies whatever your service type.
Malignant neoplasm of the colon and rectum
RH No. 19 of 2022 · BoP No. 20 of 2022
Reasonable Hypothesis — factor (18): “having sarcoidosis at the time of the clinical onset of malignant neoplasm of the colon or rectum” [clinical onset]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Non-melanoma malignant neoplasm of the skin
RH No. 78 of 2024 · BoP No. 79 of 2024
Reasonable Hypothesis — factor (23): “having sarcoidosis at the time of clinical onset” [clinical onset]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Pericarditis
RH No. 90 of 2023 · BoP No. 91 of 2023
Reasonable Hypothesis — factor (24): “having sarcoidosis or amyloidosis at the time of the clinical onset or clinical worsening of pericarditis” [onset and worsening]
Balance of Probabilities — factor (24): “having sarcoidosis or amyloidosis at the time of the clinical onset or clinical worsening of pericarditis” [onset and worsening]
Peripheral neuropathy
RH No. 72 of 2023 · BoP No. 73 of 2023
Reasonable Hypothesis — factor (4): “having sarcoidosis at the time of the clinical onset of peripheral neuropathy” [clinical onset] — factor (35): “having sarcoidosis at the time of the clinical worsening of peripheral neuropathy” [worsening]
Balance of Probabilities — factor (4): “having sarcoidosis at the time of the clinical onset of peripheral neuropathy” [clinical onset] — factor (35): “having sarcoidosis at the time of the clinical worsening of peripheral neuropathy” [worsening]
Peritoneal adhesions
RH No. 9 of 2025 · BoP No. 10 of 2025
Reasonable Hypothesis — factor (17): “having peritoneal sarcoidosis at the time of clinical onset” [clinical onset]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Spinal adhesive arachnoiditis
RH No. 74 of 2020 · BoP No. 75 of 2020
Reasonable Hypothesis — factor (17): “having sarcoidosis before the clinical onset of spinal adhesive arachnoiditis” [clinical onset] — factor (33): “having sarcoidosis before the clinical worsening of spinal adhesive arachnoiditis” [worsening]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Transverse myelitis
RH No. 71 of 2021 · BoP No. 72 of 2021
Reasonable Hypothesis — factor (4): “having sarcoidosis at the time of the clinical onset of transverse myelitis” [clinical onset]
Balance of Probabilities — factor (4): “having sarcoidosis at the time of the clinical onset of transverse myelitis” [clinical onset]
Trigeminal neuralgia or trigeminal neuropathy
RH No. 84 of 2024 · BoP No. 85 of 2024
Reasonable Hypothesis — factor (12): “having rheumatoid arthritis or sarcoidosis at the time of clinical onset or clinical worsening of trigeminal neuropathy” [onset and worsening]
Balance of Probabilities — factor (12): “having sarcoidosis at the time of clinical onset or clinical worsening of trigeminal neuropathy” [onset and worsening]
Other accepted conditions that also open acute myeloid leukaemia
If any of these is also on your file, it reaches some of the same conditions sarcoidosis does.
What DVA means by sarcoidosis
A claim is tested against the definition first. If the diagnosis on your file does not meet this wording, the factors below never get reached — so it is worth checking that what your doctor wrote matches what the instrument requires.
Sarcoidosis, for the purposes of the Statement of Principles, for the purposes of this Statement of Principles, sarcoidosis means a chronic, multisystem disorder characterised in affected organs by an accumulation of T lymphocytes and mononuclear phagocytes, non- caseating epithelioid granulomas, and derangement of the normal tissue architecture. (3) While sarcoidosis attracts ICD-10-AM code D86, in applying this Statement of Principles the meaning of sarcoidosis is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
RH No. 60 of 2025 · BoP No. 61 of 2025 · 3 factors
What could support a claim for sarcoidosis?
The Statement of Principles for sarcoidosis names 1 other condition among its own factors. If any of these is already accepted on your file, it may be the factor that carries a sarcoidosis claim — quoted here from the instrument.
Human immunodeficiency virus infection
Reasonable Hypothesis — factor (2): “being treated for human immunodeficiency virus infection with antiretroviral drugs within the 2 years before clinical onset or clinical worsening” [onset and worsening]
Reviewed by Dr Thomas Perkins
Founding doctor, Veterans Health Centre · former RAAF aviation medical officer · 13 years working exclusively with ADF members and veterans. Full profile →
Sarcoidosis accepted?
Contact us for more information.